Although their patent protection has expired, big-name blockbusters continue to produce huge revenues for the pharmaceutical companies that produce them. Take a look at how some well-known drugs may no longer be making headlines, but continue to be big earners.
Author: Jessica Merrill
Published: 21 June 2018
Number of pages:3
From Crestor to Lipitor, Plavix to Zetia, drugs that made headlines for their blockbuster commercial sales when first launched may no longer have patent protection and make the news, but continue to constitute an important portion of revenue for the companies that manufacture them, providing padding for the bottom line, and in some cases, remaining top sellers. Take a look at these vital products and learn how these drugs may have decreased in blockbuster status, but continue to play an essential role in drug portfolios.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.